HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

This month's Leading Edge editorial discusses the difference between perception of risk and the actual risk by drawing upon two recent examples: breast cancer and the pill, and cannabis smoking and cancer risk. In both situations, scientific evidence does not appear to be affecting the public's misperception of absolute risk, and more worryingly, in the case of cannabis smoking, even nationwide policy is being lead by personal views rather than scientific evidence.

The editorial concludes: "Unravelling a misguided perception of risk from the real facts is a difficult task, but it is essential if the perpetuation of poorly conceived ideas is to stop. In light of the current trend towards chemoprevention to reduce a person's risk of contracting cancer, it is important that the general public do not become disenfranchised from the medical community by exposure to over-reporting of contradictory reports in the popular media. Only then will cancer risk truly decrease by informed changes in lifestyle."

Reviews:

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention

Cigarette smoking and the risk of endometrial cancer

Strategic marketing in the UK tobacco industry

Hyperthermia in combined treatment of cancer

Metastasis to and from the central nervous system-the "relatively protected site"

Stem-cell origin of metastasis and heterogeneity of solid tumours

The Lancet Infectious Diseases (TLID)

Combination antiretroviral therapies are widely used for the treatment of HIV but it is unclear whether they will continue to be effective in the face of quickly evolved drug-resistant strains of HIV, and increased risky sexual behaviour in certain communities. In the August issue of The Lancet Infectious Diseases, J X Velasco-Hernandez and colleagues, from the Instituto Mexicano del Petroleo, San Bartolo, Mexico, and the UCLA School of Medicine, Los Angeles, US
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
31-Jul-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO and the Lancet Infectious Diseases TLID

(Date:9/1/2015)... ... ... For many men, the first thing they notice when they go to button their white ... fitting shirt with a collar that doesn’t close against the skin, creating a sloppy look. ... all day because it’s uncomfortable. Now men in suits will be able to do ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( ... fall collection. Every customer who buys an Earth Brand shoe will be given ... with Trees for the Future, a nonprofit dedicated to planting more trees. Earth ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty ... “The Beauty Behind the Fashion” on Thursday, Oct. 1, at the La Valencia ... the spotlight on the collaboration between fashion and professional hair, makeup and nail design. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... to efficiently cure and prevent different malignancies. Some options for cancer treatment ... properties due to which distinctive approach is necessary for effective treatment. Several ...
(Date:9/1/2015)... ... 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and ... her firm’s success in the hair care and distribution industry through her combination ... will be providing “Look and learn” live demonstrations, as well as promoting her ...
Breaking Medicine News(10 mins):Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
(Date:9/1/2015)... OAKS, Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) ... (STudy evaluating effect of RomosozUmab Compared with Teriparatide ... for fracture pReviously treated with bisphosphonatE therapy). The ... statistically significant difference in favor of romosozumab in ...
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... 1, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, is scheduled to present at ... Hyatt Regency Boston in Boston, Massachusetts ... Michael A. Mussallem , Edwards Lifesciences, chief executive officer, ... a company discussion with conference attendees at 10:10 a.m. ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
Cached News: